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Background: Progression of neurodegenerative diseases occurs when microglia, upon persistent activation,
perpetuate a cycle of damage in the central nervous system. Use of mesenchymal stem cells (MSC) has been
suggested as an approach to manage microglia activation based on their immunomodulatory functions. In the
present study, we describe the mechanism through which bone marrow-derived MSC modulate the proliferative
responses of lipopolysaccharide-stimulated BV2 microglia.
Methods: BV2 microglia were cultured with MSC and stimulated with 1 μg/ml lipopolysaccharide. Using an
inducible nitric oxide synthase inhibitor, tritiated thymidine (3H-TdR) incorporation assay was performed to
determine the role of nitric oxide in the anti-proliferative effect of MSC. We also studied apoptosis and the cell cycle
of both cell types using flow cytometry and explored their cytokine profile using protein and cytometric arrays.
Moreover, the role of IL-6 and TNF-α in immunomodulation was deduced using specific blocking antibodies and
recombinant proteins.
Results: MSC reduces microglia proliferation upon lipopolysaccharide stimulation by 21 to 28% and modulates the
levels of nitric oxide, IL-6 and TNF-α. The role of nitric oxide in conferring the anti-proliferative effect of MSC was
ruled out. Furthermore, we found that MSC exert their anti-proliferative effect by restoring the percentage of BV2
cells at S and G2/M phase to levels similar to unstimulated cells. MSC undergo a G0/G1 arrest while exerting this
effect. We have also identified that MSC-mediated modulation of microglia is independent of IL-6, whilst reduction
of TNF-α in co-culture is critical for inhibition of microglia proliferation.
Conclusions: Our study demonstrates that MSC inhibit microglia proliferation independent of nitric oxide and IL-6,
although reduction of TNF-α is critical for this effect. The inhibition of proliferation is through cell cycle modulation.
These findings shed light on the mechanisms of microglial immunomodulation by MSC.
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Mesenchymal stem cells (MSC) are a group of clono-
genic, non-haematopoietic, plastic adherent multi-potent
stromal cells that possess potential to differentiate into
cells of mesodermal lineage [1,2]. MSC have been shown
to ameliorate disease in numerous clinical trials and animal
models. Approximately 400 clinical trials using MSC are
currently underway according to the clinical trials registry
of the US National Institute of Health (http://clinicaltrials.
gov). It is noteworthy that a good proportion of these
studies are exploring the immunomodulatory properties of
MSC. This aspect of MSC is widely explored in managing
graft-versus-host disease [3] and in a variety of experimen-
tal disease models, including autoimmune encephalomyeli-
tis [4], stroke [5], amyotrophic lateral sclerosis [6], spinal
cord injury [7], diabetes [8] and myocardial infarction [9].
These advances at the therapeutic level are a result of de-
tailed descriptions on the potential of MSC to modulate a
range of immune cells including T cells, B cells, dendritic
cells, monocytes and macrophages [10-15].
Microglia are resident macrophages of the central ner-
vous system (CNS), derived from primitive myeloid pro-
genitors that migrate from the embryonic yolk sac to
the brain rudiment [16]. In adults, microglia survey the
entire brain every couple of hours through concerted
movements [17] for damaged neurons, endogenous disease
proteins, and infection [18]. Microglia assume functions
beyond being immune sentinels by maintaining a healthy
CNS environment through synaptic pruning [19-21] and
secretion of neurotrophic factors [22,23]. In response to
disturbances in CNS homeostasis microglia undergo
morphological, phenotypic and functional changes. These
changes include an increase in numbers through prolifera-
tion, a shift from ramified to amoeboid morphology,
secretion of inflammatory mediators such as cytokines,
chemokines and reactive oxygen and nitrogen species,
and an increase in phagocytic activity. Experiments have
shown that these changes which microglia undergo
upon activation can cause deleterious effects within the
CNS microenvironment and play a key role in patho-
genesis of neurodegenerative disease [24-27].
Modulating microglia responses is being considered
as an effective approach to manage progression of neu-
rodegenerative diseases. Recently, with the rise in re-
ports on immunomodulatory prospects of MSC, we and
others have explored and described the potential of
MSC to dampen inflammatory responses of microglia
[28-32]. However, the mechanisms underlying these
effects are poorly understood. The present study deter-
mined the mechanisms through which MSC confer an
anti-proliferative effect on microglia by examining apop-
tosis and cell cycle. We also determined the role of nitric
oxide, IL-6 and TNF-α in conferring the modulatory
effects of MSC. It was also demonstrated that MSCexperience growth arrest in co-culture while modulating
microglial responses.Materials and methods
Mouse bone marrow mesenchymal stem cell culture
MSC previously isolated from ICR mouse bone marrow
were obtained from the culture collection of the Im-
munology Laboratory, Faculty of Medicine and Health
Sciences, Universiti Putra Malaysia. Frozen vials stored
in liquid nitrogen were thawed at 37°C and cultured in
MSC complete medium (high glucose DMEM (GIBCO
Invitrogen, CA, USA), supplemented with 15% (v/v)
MesenCult® Mesenchymal Stem Cell Stimulatory Sup-
plements (Mouse) (Stemcell™ Technologies, Canada),
1% penicillin and streptomycin (iDNA), 250 μg/ml fun-
gizone (GIBCO Invitrogen, CA, USA), 2.0 mM Gluta-
MaX and 1.5 g sodium bicarbonate) at 37°C, 5% CO2 in
a humidified incubator. Cells were routinely sub-cultured
using 0.25% Trypsin-EDTA (GIBCO Invitrogen, CA, USA)
before reaching 90% confluency and immunophenotyped
using a panel of markers comprising CD106, CD45, CD44,
CD11b, Sca-1, MHC-I and MHC-II (all from Becton
Dickinson, BD, San Jose, CA, USA) [1]. MSC phenotype
was confirmed by positivity to CD106, CD44, Sca-1 and
MHC-I and negativity to CD45, CD11b and MHC-II.BV2 microglia culture
BV2 cells were a generous gift from Dr Thameem
Dheen of the National University of Singapore. BV2 is a
murine microglial cell line immortalised with v-raf/v-myc
genes carrying retrovirus J2 [33]. Cells were cultured in
DMEM with 5% heat-inactivated foetal bovine serum, 100
U/ml penicillin, 100 μg/ml streptomycin, 10 g/ml genta-
micin (all Invitrogen), 1 × non-essential amino acids and
6.25 μg/ml insulin (Sigma-Aldrich, St. Louis, MO, USA).
Cells were either sub-cultured or used for downstream
assays before reaching 90% confluency by harvesting
with 0.25% trypsin containing 1 mM EDTA for 5 mi-
nutes at 37°C.MSC/BV2 co-cultures
BV2 and MSC were seeded simultaneously at a ratio of
1:0.2 and incubated overnight at 37°C in a 5% CO2 incu-
bator to allow cells to adhere. Co-cultures were then
stimulated with 1 μg/ml lipopolysaccharide (LPS; E. coli
serotype O26:B6; Sigma Cat. No. L2762). This culture set-
up will be described as ‘activated co-cultures’ hereafter.
The time point of LPS addition was considered as 0 hour
for all experiments. Cell culture inserts with a 1 μm poly-
ethylene terephthalate membrane pore size (Falcon, BD
Biosciences, Erembodegem, Belgium) were used for trans-
well experiment set-up.
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BV2 cell proliferation was determined by assessing triti-
ated thymidine (3H-TdR; Perkin Elmer, Boston, USA) in-
corporation. In 96-well plates, 1 × 103 MSC were seeded
in triplicate and allowed to adhere overnight. The follow-
ing day, MSC were treated with 10 μg/ml mitomycin-C
(Sigma) for 2 hours to halt their proliferation. Plates were
washed thoroughly with DMEM to remove any traces of
the mitotic inhibitor and BV2 cells were then seeded at
5 × 103 cells/well. Co-cultures were activated with 1 μg/ml
LPS for 48 hours and 3H-TdR (0.037 MBq/well (0.5 μCi/
well)) was added to wells at the final 6 hours of incuba-
tion. Plates were exposed to a freeze/thaw cycle at -20°C
to ease cell harvesting. Cells were harvested onto a filter
mat by using an automated cell harvester (Harvester
Mach III M, TOMTEC, CT, USA Thymidine incorpor-
ation was measured by liquid scintillation spectroscopy
on a beta counter (MicroBetaTriLux, Perkin Elmer Boston,
USA) after the addition of scintillation fluid (OptiPhaseSu-
perMix Cocktail; Perkin Elmer Boston, USA) and readouts
were in counts per minute (cpm).
Griess assay
Nitric oxide (NO) was detected in the supernatant of
cultures using the Griess assay. For this, 50 μl culture
supernatant from each sample was transferred to a 96-well
plate in triplicate and an equal volume of Griess reagent
added (1% sulphanilamide/0.1% N-1-napthylethylene-
diamine dihydrochloride/2.5% phosphoric acid; all from
Sigma). Absorbance was read at 530 nm (MRX II micro-
plate reader, Dynex, VA, USA) after 10 minutes incuba-
tion. Nitrite concentration was calculated with reference
to a standard curve of freshly prepared sodium nitrite (0




Apoptosis of cells in co-culture was determined by flow
cytometry after double staining with FITC-Annexin-V
and propidium iodide (PI). BV2 cells and MSC were co-
cultured overnight at a 1:0.2 ratio, stimulated with 1 μg/
ml LPS the following day, and left in culture for 48 hours.
Cells were then harvested using 0.25% trypsin-EDTA.
Cells were washed twice in ice-cold PBS and suspended
in 100 μl of 1X binding buffer at a concentration of 1 ×
106 cells/ml. Cells were stained for CD45 by incubating
with 0.5 μl antibody (Rat anti-mouse CD45, BioLegend®,
San Diego, CA, USA ) at 4°C for 15 minutes followed by
15 minutes incubation with secondary antibody (DyLight™
649 Goat anti-rat IgG, BioLegend®). CD45 staining was
performed to distinguish BV2 microglia from the MSC
population during flow cytometry analysis. Five microlitres
each of FITC-conjugated Annexin-V and PI was added
to each tube and incubated for 15 minutes at roomtemperature. Four hundred microlitres of 1X binding
buffer was added to each tube before acquisition and
analysis using a flow cytometer.
Cell cycle analysis
Distribution of cells through the three distinct phases of
cell cycle (G0/G1, S and G2/M phase) was analysed
using PI staining. Co-cultures were harvested using 0.25%
trypsin-EDTA and washed once in PBS by centrifugation
at 1,000 rpm for 7 minutes. Cells were then suspended in
1 ml of ice-cold PBS at a density of 0.5 × 106 cells per tube.
The cell suspension was subsequently added drop wise to
3 ml ice-cold 95% ethanol for fixation. The tubes were in-
cubated at -20°C for at least 2 hours. The tubes were re-
moved from -20°C and spun at 1,200 rpm for 10 minutes
and washed once using ice-cold PBS to remove traces of
ethanol. The cells were then suspended in 500 μl of 50 μg/
ml PI staining solution and incubated at 37°C for 15 mi-
nutes. Stained cells were washed once with PBS to remove
excess PI and suspended in 400 μl PBS. The cell cycle data
for individual samples were acquired using the BD LSR
Fortessa™ flow cytometer equipped with BD FACSDiva™
software (BD) and analysed using ModFit LT™ software
(Verity Software House, ME, USA).
Cytokine bead array/protein array for TNF-α and IL-6
detection
Co-culture supernatants were assayed at 24 hours using
a custom RayBio® mouse cytokine array kit (RayBiotech,
Inc., GA, USA ), according to manufacturer’s instructions.
The results are expressed as relative protein levels com-
pared with LPS-stimulated BV2 cells. Absolute quantity of
IL-6 and TNF-α in culture supernatants were then deter-
mined at 24 hours by using a multiplex bead array kit (BD
Cytometric Bead Array mouse inflammation kit; BD
Biosciences, San Jose, CA, USA), according to the manu-
facturer’s instructions. Samples were assayed on a FACS
Fortessa flow cytometer (BD Biosciences) and analysed
with FCAP array software (BD Biosciences). Concentra-
tion of cytokines in samples was calculated using individ-
ual standard curves and expressed as pg/ml.
Cytokine blocking studies
Specific blocking antibodies to TNF-α and IL-6 were
used to elucidate the functional importance of modula-
tion of these cytokines in co-culture. Blocking antibodies
against TNF-α (XT3.11), IL-6 (MP5-20 F3) and isotype
(Rat IgG1) control (all from Bio X Cell, NH, USA) were
reconstituted in 1X PBS to 1.0 mg/ml. The antibodies
were then serially diluted in culture media to obtain
working stock concentrations of 20.0, 2.0 and 0.2 μg/ml.
Cells were plated either in 12-well plates (for Griess as-
says) or in 96-well plates (for proliferation assays) as de-
scribed earlier. Cells were stimulated with 1 μg/ml LPS
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body were added to cultures to obtain a final concentration
of 10.0, 1.0 and 0.1 μg/ml. Culture supernatants were col-
lected at 24 and 48 hours and assayed for NO production
using Griess assay. Proliferation was analysed at 48 hours
by pulsing the cultures with 3H-TdR for the final 6 hours
of incubation.
Statistical analysis
Mean values and standard deviations (SD) were calcu-
lated from three independent experiments and signifi-
cance was assessed using one-way analysis of variance
followed by the Tukey post hoc test or student’s t test
using GraphPad Prism version 6 (GraphPad software, San
Diego, CA, USA).
Results
Mesenchymal stem cells inhibit BV2 microglia proliferation
independent of nitric oxide
An in vitro model of microglia proliferation was estab-
lished by examining BV2 microglia proliferation in re-
sponse to LPS stimulation at 6, 24 and 48 hours. The
proliferation rate of BV2 microglia appeared unaffected by
LPS at 6 and 24 hours (Additional file 1: Figure S1a,b). At
48 hours, LPS-stimulated microglia displayed an approxi-
mate 30% increase in proliferation (Figure 1a, P < 0.01;
Additional file 1: Figure S1c). This increase in microglia
proliferation was used as a model to test the anti-
proliferative effect of MSC.
To study the mechanisms through which MSC exert
their anti-proliferative effect on microglia, the BV2:MSCFigure 1 Mesenchymal stem cells inhibits BV2 microglia proliferation
cells (MSC) were seeded at a 1:0.2 ratio in a 96-well plate with 1 μg/ml lipo
(L-NAME) for 48 hours, and BV2 proliferation was determined with a tritiate
mean ± SD of percentage BV2 proliferation from three independent experim
using the Griess assay. BV2 cells and MSC were cultured in 12-well plates a
assayed at 48 hours. Values are expressed as mean ± standard deviation of
cells; #P < 0.01, versus BV2 + LPS.ratio of 0.2 was selected based on previous reports from
our laboratory [28,34] (see Additional file 2: Figure S2
for images of BV2/MSC co-culture). Co-culturing with
MSC at a 0.2 ratio decreased LPS-induced proliferation
of BV2 microglia by 28.77 ± 7.90% at 48 hours (Figure 1a,
P < 0.01), similar to proliferation rates of unstimulated BV2
microglia. MSC were mitotically arrested by mitomycin-C
(10 μg/ml) treatment (Additional file 1: Figure S1d,e) to fa-
cilitate accurate measurement of microglia proliferation in
co-culture.
A previous report from our laboratory demonstrated that
MSC generate NO upon exposure to soluble factors from
microglia, while BV2/MSC co-culture induces a surge in
NO levels beyond that of LPS-stimulated microglia [34].
When tested in this study, co-culture of BV2:MSC at a
1:0.2 ratio induced a 25% surge in NO levels from 56.94 ±
2.65 μM to 76.59 ± 3.08 μM at 48 hours (Figure 1b; P <
0.01). Within an immunomodulatory paradigm, NO has
been shown to play a vital role in MSC-mediated suppres-
sion of activated T cell proliferation [35,36]. These reports,
with the use of MSC derived from inducible nitric oxide
synthase (iNOS)-/- mice, have pinpointed that NO gen-
erated by MSC in the co-culture paradigm plays a vital
role in reducing T cell proliferation. We used N-nitro-
L-arginine methyl ester (L-NAME), a specific inhibitor
of NOS, to address the role of NO in conferring the
anti-proliferative effect of MSC on BV2 microglia. We
tested a series of L-NAME concentrations (50, 125, 250,
500, 750 and 1000 μM) on LPS-stimulated BV2 microglia
(Additional file 3: Figure S3) and demonstrated that even
reducing the NO levels in co-culture to levels comparableindependent of nitric oxide. (a) BV2 cells and Mesenchymal stem
polysaccharide (LPS) and 1000 μM N-nitro-L-arginine methyl ester
d thymidine (3H-TdR) incorporation assay. Values are expressed as
ents. (b) NO2
- concentration in culture supernatant was determined
t a 0.2 ratio (BV2: MSC) and stimulated with 1 μg/ml LPS, and NO2- was
NO2
- in μM from three independent experiments. *P < 0.01, versus BV2
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does not alter the anti-proliferative effect conferred by
MSC (Figure 1a).Co-culture does not induce apoptosis
Data from the 3H-TdR assays indicate that the reduction
of microglial proliferation results from a decreased num-
ber of actively proliferating cells. Such reductions could
also occur due to induced death of the responder cells
as reported for MSC–T cell interactions [37], apart from
the inhibition of proliferation postulated here. Thus, we
sought to determine whether co-culture induces cell death
in microglia. When BV2 cells were co-cultured with MSC,
the proportion of apoptotic cells as examined by Annexin
V and PI staining (Figure 2a) of the CD45+ population
(Additional file 4: Figure S4a,c) was not altered. The aver-
age percentage viability (Annexin-V-/PI-) of BV2 cells
remained higher than 94.0 ± 1.7% (Additional file 5:
Table S1) across all samples tested, ruling out the process
of apoptosis as a compounding factor in inhibition of BV2
proliferation by co-culture. Similarly, no significant cell
death was noted for MSC (CD45- population; Additional
file 4: Figure S4b,c) in co-culture (Figure 2b and Additional
file 5: Table S1).Figure 2 Co-culture does not induce apoptosis in BV2 cells and mese
left), early apoptotic (lower right), late apoptotic (upper right) and necrotic
cells (MSC) as determined by Annexin-V/propidium iodide (PI) staining 48 h
each quadrant of plot indicates percentage of cells. Results are from a reprMesenchymal stem cells inhibit BV2 microglia proliferation
through contact-dependent cell cycle modulation
MSC in co-culture are shown to induce cell cycle arrest
of target cells (splenocytes, dendritic cells and in tumour
cells) at G0/G1 phase [12,14,38]. Experiments were per-
formed in order to test whether MSC induce similar ef-
fects on microglia. At 48 hours, LPS stimulation induced
a surge of BV2 microglia in the S phase of the cell cycle
from 40.0 ± 0.4% to 57.4 ± 1.2% (P < 0.01) and direct co-
culture with MSC reduced the percentage of BV2 micro-
glia in S phase to 42.7 ± 1.1 (P < 0.01), levels comparable
to resting BV2 cultures (Figure 3a). Experiments were
also performed with MSC separated from BV2 cells in
culture wells by transwell inserts of 1 μm pore size to
determine the importance of cell-to-cell contact in cell
cycle modulation. The transwell system physically sepa-
rates BV2 microglia and MSC but permits the transfer
of soluble factors and thus enables the demarcation of
the role of soluble factors and cell-to-cell contact. MSC
in transwell (in the absence of cell-to-cell contact) did
not induce a significant change in the percentage popu-
lation of BV2 cells in S phase (53.4 ± 2.4) compared with
LPS-stimulated BV2 cells, revealing that cell-to-cell con-
tact is critical for MSC-mediated modulation of BV2
microglia cell cycling.nchymal stem cells. Scatter plots show percentage of viable (lower
(upper left) populations in (a) BV2 cells and (b) mesenchymal stem
ours post-lipopolysaccharide (LPS) stimulation. The number within
esentative of three independent experiments.
Figure 3 Mesenchymal stem cells inhibit microglia proliferation through contact-dependent cell cycle modulation. BV2 and
Mesenchymal stem cells (MSC) were cultured at a 1:0.2 ratio and stimulated with 1 μg/ml lipopolysaccharide (LPS) after overnight incubation.
Cells were harvested 48 hours post-LPS stimulation and cell cycle was analysed by propidium iodide staining. Separation of BV2 and MSC
populations on flow cytometry was enabled by CD45 staining (see Additional file 3: Figure S3). Histograms show distribution of (a) BV2 cells and
(b) MSC from direct co-culture across G0/G1, S and G2/M phases of cell cycle at 48 hours after LPS stimulation and/or co-culture. Values are
expressed as mean ± standard deviation of percentage of cells from three independent experiments. (a) *P < 0.01, versus BV2 cells; #P < 0.01,
versus BV2 + LPS. (b) *P < 0.001, versus MSC; #P < 0.001, versus MSC + LPS.
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BV2 proliferation in co-culture is indeed an arrest, their
cell cycle was further analysed at 24, 48, 72 and 96 hours
(Table 1) in separate experiments. MSC did not induce cell
cycle arrest in BV2 cells at any of the time points tested
but continued to restore the cell cycle of LPS-stimulated
BV2 microglia to that of resting BV2 cells (BV2 microglia
cells alone).
Interestingly, co-culture exerted a G0/G1 arrest in
MSC cell cycle by 48 hours. Presence of microglia in the
culture induced an approximate 20% increase of MSC at
the G0/G1 phase (Figure 3b; P <0.001). The surge was
more prominent when cultures were stimulated with
LPS; LPS-activated microglia retained most of the MSC
at G0/G1 phase (86.32 ± 2.05%; P < 0.001). Neither MSC
cell cycle (Figure 3b) nor proliferation (Additional file 1:
Figure S1f ) was affected by exposure to LPS alone. Cell
cycle arrest of MSC in co-culture may also be induced
by contact inhibition and/or media deprivation. In order
to negate these possibilities, the cell seeding density of
both MSC and BV2 were reduced by 10 times in co-
culture and MSC cell cycle was analysed. Even at such low
seeding density, where probabilities of contact inhibitionTable 1 Co-culture with Mesenchymal stem cells continues to
induce a cell cycle arrest
Cell cycle distribution (BV2 Microglia: MSC direct coculture)
BV2 BV2 + LPS
G0/G1 S G2/M G0/G1 S
24 hrs 42.8 ± 1.5 49.3 ± 3.7 7.0 ± 2.5 34.2 ± 0.6* 6
48 hrs 50.7 ± 1.9 44.2 ± 1.1 4.7 ± 1.2 38.2 ± 1.2* 5
72 hrs 77.6 ± 0.9 19.3 ± 0.9 3.1 ± 0.1 48.2 ± 1.5* 5
96 hrs 83.8 ± 4.0 14.1 ± 3.7 2.1 ± 2.3 63.2 ± 1.3* 3
BV2 cells and Mesenchymal stem cells (MSC) were seeded at a 1:0.2 ratio in 6-well
Cell cycle analysis of BV2 cells (CD45 + ve population in co-culture) was performed
mean percentage population of BV2 cells ± standard deviation from three independ
†P < 0.05, ‡P < 0.05, versus the corresponding phases in BV2 + LPS.or media deprivation was minimal, MSC cell cycle was
arrested as early as 24 hours when in co-culture with BV2
microglia (Additional file 6: Figure S5).
Mesenchymal stem cells modulate the cytokine profile of
co-cultures
Culture supernatants were examined using a glass slide-
based protein array to identify soluble proteins involved
in MSC-mediated immunomodulation of microglia. From
this array it was observed that IL-6 and TNF-α were sig-
nificantly modulated by co-culture. BV2 microglia in cul-
ture produced negligible amounts of IL-6 and TNF-α
(Figure 4a,c). LPS stimulation increased the expression of
both cytokines at 24 hours. Co-culture with MSC in the
presence of LPS further induced a 25.5 ± 6.5% surge in IL-
6 (Figure 4a, P < 0.001), whilst TNF-α levels were reduced
to 33.2 ± 17.3% (Figure 4c, P < 0.001). These cytokines
were then quantified using a cytometric bead array. Con-
sistent with the results from protein array, IL-6 produc-
tion was negligible in BV2 cultures (~9 pg/ml; Figure 4b).
LPS stimulation increased IL-6 levels to 683.1 ± 55.4 pg/
ml by 24 hours and the presence of MSC increased IL-6
levels to 3,693.8 ± 751.1 pg/ml in LPS-treated BV2modulate BV2 cell cycle until 96 hours but does not
BV2 +MSC + LPS
G2/M G0/G1 S G2/M
2.0 ± 3.8# 3.8 ± 3.3 44.3 ± 1.8† 50.1 ± 1.0‡ 5.6 ± 4.9
9.0 ± 2.7# 1.8 ± 2.2 43.9 ± 1.9† 48.6 ± 1.2‡ 6.3 ± 3.7
1.6 ± 1.8# 0.3 ± 0.3 52.4 ± 5.6 41.3 ± 2.4‡ 1.9 ± 3.0
5.7 ± 21.1# 1.0 ± 1.1 75.6 ± 1.7† 18.4 ± 0.9‡ 6.0 ± 1.1€
plates and left overnight prior to lipopolysaccharide (LPS) stimulation (1 μg/ml).
using propidium iodide (PI) staining at the time points indicated. Data show
ent experiments. *P < 0.05, #P < 0.05, versus respective BV2 alone controls.
Figure 4 Mesenchymal stem cells modulate the expression of IL-6 and TNF-α in microglia co-culture. Microglia (BV2 cells or primary
microglia) and Mesenchymal stem cells (MSC) were seeded simultaneously into 24-well plates at a 1:0.2 ratio. Cells were left overnight in culture
and stimulated with 1 μg/ml lipopolysaccharide (LPS). Culture supernatants were collected 24 hours later and expression of (a,b) interleukin
(IL)-6 and (c,d) tumour necrosis factor (TNF)-α were analysed using the RayBio antibody array (a,c) or BD Cytokine Bead Array (b,d). Protein array
results are expressed as mean relative protein level ± standard deviation from two independent experiments and cytokine bead array results are
expressed in mean concentration (pg/ml) ± standard deviation from three independent experiments. *P < 0.001, versus BV2 cells; #P < 0.001,
versus BV2 + LPS.
Figure 5 IL-6 does not play a role in mesenchymal stem cell (MSC)-mediated modulation of nitric oxide and proliferation in BV2:MSC
co-cultures. BV2 cells and MSC were seeded at a 1:0.2 ratio into 12-well plates (Griess assay) or 96-well plates (proliferation assay). After overnight
incubation, 1 μg/ml lipopolysaccharide (LPS) and interleukin (IL)-6 blocking antibodies at concentrations indicated below the graph were added
to co-cultures and (a) proliferation and (b) NO2
- concentration were analysed at 48 hours. Values are expressed as mean ± standard deviation
from three independent experiments. Controls are respective cultures without blocking antibodies. *P < 0.05, versus control BV2 cells; #P < 0.05,
versus control BV2 + LPS.
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of MSC reduced TNF-α levels to 852.1 ± 134.9 pg/ml
compared with 1,271.2 ± 294.2 pg/ml (Figure 4d) in
LPS-stimulated BV2 cells alone.
Mesenchymal stem cell-mediated inhibition of microglial
proliferation is independent of IL-6
LPS stimulation induced proliferation of BV2 microglia
by 32.24 ± 4.5% and co-culture of BV2 microglia and
MSC at the 0.2 ratio reduced LPS-stimulated proliferation
of BV2 microglia by 21.50 ± 3.32% (Figure 5a, P < 0.05). In
order to identify whether the surge in IL-6 in BV2/MSC
co-culture is responsible for the anti-proliferative effect of
MSC, IL-6 from cultures was neutralised using anti-mouse
IL-6 blocking antibody. An isotype IgG was used as a con-
trol to negate any non-specific effects. Addition of isotype
IgG did not induce any changes (data not shown). Neutra-
lising IL-6 from cultures did not influence the proliferation
of LPS-stimulated microglia nor the anti-proliferative effectFigure 6 Nitric oxide surge in co-culture and reduction in microglial p
mesenchymal stem cells (MSC) were seeded at a 0.2 ratio into 96 well plat
(a,c) tumour necrosis factor (TNF)-α blocking antibodies or (b,d) recombin
and NO2
- concentration (a,b) and proliferation (c,d) was analysed at 48 hou
independent experiments. Controls are culture wells without blocking antib
control BV2 + LPS; фP < 0.05, ффP < 0.001, versus control co-culture + LPS.of MSC (Figure 5a). It was also demonstrated that IL-6
did not influence the NO production within the MSC-
mediated immunomodulatory paradigm (Figure 5b).
Mesenchymal stem cells inhibit microglial proliferation by
reducing TNF-α
We sought to determine the role of TNF-α in MSC-
mediated immunomodulation of microglial responses
and first addressed whether application of blocking anti-
bodies could affect the NO profile. Similar to that
demonstrated previously, co-culture induced a surge in
LPS-induced NO production (Figure 6a). Neutralising
TNF-α did not affect NO levels in LPS-stimulated BV2
cultures, but 10 μg/ml TNF-α blocking antibody signifi-
cantly reduced NO levels in co-culture (Figure 6a, P <
0.05). Next, we applied recombinant TNF-α to co-cultures
and its effect on NO expression was studied. TNF-α levels
detected in LPS-stimulated BV2 cultures by the cytokine
bead array were approximately 1.5 ng/ml. Addition ofroliferation are mediated by TNF-α modulation. BV2 cells and
es. After overnight incubation, 1 μg/ml lipopolysaccharide (LPS) and
ant TNF-α were added at concentrations indicated below the graph,
rs. Values are expressed as mean ± standard deviation from three
odies. *P < 0.05, versus control BV2 cells; #P < 0.05, ##P < 0.001, versus
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5.0 ng/ml) did not affect the NO profile of any of the
culture conditions tested (Figure 6b). However, at 50 ng/ml,
TNF-α induced NO levels in co-culture by approximately
two-fold (Figure 6b, P < 0.001 compared to activated co-
culture without recombinant TNF-α).
Next we sought to address the effect of TNF-α
deprivation on microglial proliferation. LPS stimulation
induced the proliferation of BV2 microglia by approxi-
mately 30% and in co-culture MSC reduced the prolifer-
ation of LPS-stimulated BV2 microglia by 26.13 ± 7.24%
(Figure 6c, P < 0.05). Neutralising TNF-α in LPS-stimulated
BV2 microglia cultures (without MSC) reduced their prolif-
eration in a dose-dependent manner; at 10 μg/ml, prolifera-
tion was reduced to levels similar to unstimulated BV2
microglia. As MSC reduced TNF-α levels (Figure 4c,d) in
LPS-stimulated BV2 microglia cultures, we presume that a
reduction of TNF-α by MSC may be the mechanism
through which MSC exert their anti-proliferative effect
on microglia. Further reduction in TNF-α levels did not
influence the anti-proliferative effect of MSC; percent-
age proliferation of BV2 remained between 70.57 ± 5.6%
and 72.70 ± 3.5% for all three antibody concentrations
tested (Figure 6c). Addition of recombinant TNF-α to co-
cultures abolished the anti-proliferative effect of MSC at
concentrations as low as 0.5 ng/ml, with higher concentra-
tions inducing a dose-dependent increase in microglial
proliferation (Figure 6d). At 50 ng/ml TNF-α, microglia
proliferation was induced in co-culture to 119.75 ±
5.56% (Figure 6d, P < 0.05) compared to 73.87 ± 7.24%
in the control co-culture.
On the contrary, TNF-α exerted an anti-proliferative
effect on resting BV2 microglia (Figure 6d). Addition of
TNF-α to unstimulated BV2 culture at 50 ng/ml reduced
their proliferation to 41.26 ± 4.62% (Figure 6d, P < 0.05)
compared to 66.94 ± 6.58% in the control, whereas addition
of TNF-α did not alter the proliferation of LPS-induced
BV2 microglia.
Discussion
Here, for the first time, we demonstrate the role of TNF-α
in MSC-mediated immunomodulation of microglia. Treat-
ment of BV2 microglia cultures with TNF-α blocking anti-
bodies reduced LPS-induced proliferation while addition
of recombinant TNF-α to co-cultures abolished the anti-
proliferative effect of MSC on microglia. Microgliosis is a
common response towards injury in the CNS, including
Alzheimer’s disease [39], Parkinson’s disease [40], multiple
sclerosis [41] and stroke [42], and the findings here may
prove to be beneficial for these conditions.
In addition, the present study negated the role of apop-
tosis and soluble factors such as NO and IL-6 in conferring
this effect. We also provide the first evidence that MSC
confer the inhibitory effect on microglia proliferationthrough modulation of microglia cell cycle and MSC them-
selves undergo a G0/G1 arrest while exerting this effect.
Following co-culture with MSC, microglia prolifera-
tion in response to LPS stimulation was dampened and
NO levels were increased. Surge in NO levels in MSC
co-cultures have been previously identified as the key
mechanism conferring anti-proliferative effects on T cells
[35,36]. To examine similar prospects, NO production in
co-culture was abolished using a specific iNOS inhibitor -
L-NAME - and microglia proliferation was analysed. Con-
verse to the reports in MSC/T cell co-cultures, abolishing
NO did not restore microglia proliferation in our study.
This is contradictory to a recent report which suggested
the role of NO in MSC-mediated inhibition of microglia
proliferation [43]. In the mentioned report, conditioned
media from MSC cultures treated with an iNOS inhibitor
was used to study the anti-proliferative effect, and thus
the role of microglial cues that may be required by MSC
to exert such effects was not negated. Our laboratory has
previously reported that MSC requires microglial cue to
induce a NO surge [34]. The current approach to elimin-
ate NO directly from co-culture by addition of L-NAME
efficiently negates such doubts and rules out the role of
NO in inhibition of microglial proliferation by MSC.
The inhibition of microglial proliferation reported here
could also be contributed by cell death. MSC are shown
to induce indoleamine 2,3-dioxygenase-dependent apop-
tosis of activated T cells [37]. Through examination using
Annexin-V/PI staining, we demonstrate that co-culture
with MSC does not induce apoptosis in microglia. Such
differences in interaction of MSC with T cells and micro-
glia emphasises diversity in the modulatory functions that
MSC exert on different target cell types.
Next, we examined whether co-culture induces cell
cycle modulation in microglia. Studies have shown MSC
induce cell cycle arrest in dendritic cells [14] and tumour
cells [38]. Here, for the first time, we provide evidence that
MSC exert their anti-proliferative effect through modula-
tion of microglia cell cycle. Co-culture with MSC restored
the percentage of BV2 cells in the different phases of the
cell cycle to levels comparable to resting microglia. Inter-
estingly, this modulation was dependent on cell-to-cell
contact. From a therapeutic perspective, we presume that
suppression of the proliferative response of microglia
through cell cycle modulation is beneficial, as inducing
apoptosis or a permanent cell cycle arrest may perturb the
volume of glia and hence affect homeostasis of the brain.
Interestingly, MSC entered a G0/G1-phase cell cycle
arrest while exerting the anti-proliferative effect sug-
gesting that the inhibitory effect of MSC on microglia
activation (at least in terms of microglia proliferation) is
not dependent on a need for a proliferative response
from MSC. The ability of MSC to modulate the prolifera-
tive response of microglia whilst simultaneously entering
Jose et al. Journal of Neuroinflammation 2014, 11:149 Page 10 of 13
http://www.jneuroinflammation.com/content/11/1/149a cell cycle arrest is presumably a beneficial one. Tumouri-
genic transformation of MSC has been implicated in sev-
eral experimental transplantations including osteogenic
sarcomas [44], myocardial infarction and diabetic neur-
opathy [45]. Therefore, careful evaluation and under-
standing of proliferative potential of MSC within the
inflamed milieu is necessary for the success of clinical
interventions.
We have also demonstrated here that MSC modulate
the expression of TNF-α and IL-6. Co-culture with MSC
significantly reduced the TNF-α which was upregulated
upon LPS stimulation whereas co-culture induced a surge
in IL-6. Similar modulation of cytokines was also reported
previously by us [34] and others [29,43]. The impact of
differential modulation of IL-6 and TNF-α was further de-
duced using blocking antibodies and recombinant TNF-α.
Through addition of blocking antibodies, we have identi-
fied that the IL-6 surge in co-culture does not influence
the anti-proliferative effect of MSC or NO modulation.
Distinct from IL-6, TNF-α seems to play a context-
dependent role on modulation of NO and microglial pro-
liferation in co-culture. Reducing TNF-α level in culture
using blocking antibodies did not influence the NO pro-
file of activated microglia. However, addition of recom-
binant TNF-α induced a dose-dependent NO surge in
co-cultures. It has been previously described by our
group that soluble factors from activated co-culture in-
duce NO production in MSC and these soluble factors
include TNF-α [34]. It is possible that, in co-culture, the
additional TNF-α added to the co-culture acts in tan-
gent with microglial signals to induce a surge in NO, or
TNF-α itself acts as the signal to induce NO production
by MSC. MSC are known to respond to TNF-α signals
and elicit downstream responses including NFκB trans-
location which is required for iNOS transcription [46].
However, such postulations need to be further validated.
We also showed distinct responses in microglia prolifera-
tion upon altering TNF-α levels in culture. TNF-α has
been previously identified as vital for beta-amyloid-induced
proliferation of microglia; abolishing TNF signals through
addition of anti-TNF-α antibody or a soluble TNF receptor
inhibitor both prevented beta-amyloid-induced prolifera-
tion of microglia [47]. Similarly in an MPTP mouse model
of Parkinson’s disease, knocking out TNF-α significantly
reduced microglial activation as measured by cell number
and morphology compared to wild-type controls [48], sug-
gesting the important role played by TNF-α in microglial
activation. Managing TNF-α levels in the inflammatory mi-
lieu is thus considered an efficient way to modulate inflam-
mation [48,49]. At present, there is no evidence to suggest
that modulation of TNF-α is the mechanism through
which MSC confer an anti-proliferative effect on microglia.
Likewise, there is no report on how MSC reduce microglial
TNF-α. However, earlier reports from our laboratory [34]and the present study confirms the potential of MSC to
downregulate TNF-α production in an LPS-stimulated
microglia co-culture paradigm. Similarly, intravenous
transplantation of MSC into rat traumatic brain injury
models significantly decreased TNF-α levels in the in-
jured cortex and decreased the number of glial cells at
the site of injury [50]. Thus, we hypothesised that modula-
tion of TNF-α by MSC may be vital in conferring their
anti-proliferative effect and monitored the effects of neu-
tralising TNF-α and adding recombinant TNF-α on prolif-
eration of LPS-stimulated BV2 microglia in co-culture.
Abolishing TNF-α from co-culture did not enhance the
anti-proliferative effect of MSC, indicating that a further
decrease of TNF-α from that seen in co-cultures does not
have an additive effect on MSC anti-proliferation of BV2.
Also, the basal proliferation of BV2 cells may not require
TNF-α, as addition of anti-TNF onto unstimulated BV2
did not affect their proliferation. However, the prolifera-
tion of LPS-stimulated microglia was reduced in a dose-
dependent manner upon addition of TNF-α neutralising
antibodies, thus confirming the role of TNF-α in inducing
proliferation of microglia. It is noteworthy that addition
of recombinant TNF-α to LPS-stimulated BV2 culture
did not increase their proliferation. This indicates that a
critical concentration of TNF-α may be required for
microglial activation above which the cells may become
non-responsive. Also, other cues may be necessary for a
proliferative response. Considering the requirement of cell-
to-cell contact in modulating the cell cycle of activated
microglia, we suggest the involvement of one or few cell
surface molecules that may work in tandem with TNF-α
modulation to achieve the inhibition of microglia prolifera-
tion by MSC. Recent studies have strongly suggested the
role of cell surface molecules such as CD200 [51], HLA-G
[52] and PD-1 [53] expressed by MSC on their immuno-
modulatory potential. It is possible that these cell surface
ligands could be involved in the MSC-mediated modula-
tion of BV2 microglia proliferation.
Next, in order to confirm the relation of MSC-mediated
reduction of TNF-α and inhibition of microglial prolifera-
tion in co-culture, we used recombinant TNF-α. At con-
centrations as low as 0.5 ng/ml, TNF-α abolished the
inhibition of microglia proliferation in co-culture. More-
over, higher concentrations of recombinant TNF-α in-
duced the proliferation of microglia in co-culture to levels
beyond that of LPS-stimulated culture. This confirms
downregulation of TNF-α in co-culture by MSC as the
key mechanism leading to the inhibition of microglial
proliferation.
Conclusions
Our results demonstrate the role of TNF-α in MSC-
mediated immunomodulation of microglia. In addition,
the present study negated the role of apoptosis and the
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inhibition of microglia proliferation. We also provide evi-
dence that MSC confer the inhibitory effect on microglia
proliferation through modulation of microglia cell cycle
and MSC themselves undergo a G0/G1 arrest while
exerting this effect. These findings suggest the potential
use of MSC in modulating microglial responses in in-
flammatory conditions.
Additional files
Additional file 1: Figure S1. Effect of LPS on BV2 and MSC cell
proliferation and mitomycin-C on MSC. MSCs and BV2 microglia were
co-cultured at a 1:0.2 ratio and proliferation was analysed with 3H-TdR
incorporation at (a) 6 hours, (b) 24 hours and (c) 48 hours after stimulation
with 1 μg/ml LPS. MSC were cultured independently at the same seeding
density and treated with 10 μg/ml mit-C for 2 hours after overnight culture.
(d) Proliferation and (e) cell cycle was analysed 48 hours post mit-C
treatment with 3H-TdR incorporation and PI staining respectively. (f)
MSC culture was stimulated with 1 μg/ml LPS and proliferation was
analysed with 3H-TdR incorporation at 48 hours post-LPS stimulation.
Values are expressed as mean ± SD from three independent
experiments. *P < 0.05, versus respective controls. 3H-TdR, tritiated
thymidine; LPS, lipopolysaccharide; mit-C, mitomycin C; MSC, mesenchymal
stem cells; PI, propidium iodide; SD, standard deviation.
Additional file 2: Figure S2. Morphology of BV2 cells and MSC in
culture. Phase contrast images showing morphology of BV2 cells and
MSC seeded at a 1:0.2 ratio in a 6-well plate with 1 μg/ml LPS at 48 hours.
LPS, lipopolysaccharide; MSC, mesenchymal stem cells.
Additional file 3: Figure S3. L-NAME inhibits NO in a dose dependent
manner. NO2
- concentration in culture supernatant was determined using
the Griess assay at 24 and 48 hours. BV2 cells were stimulated with 1 μg/
ml LPS in the presence of different concentrations of L-NAME as
indicated below the graph and NO was assayed. Values are expressed as
mean ± SD of three independent experiments. *P < 0.01, versus BV2 cells;
#P < 0.01, versus BV2 + LPS. LPS, lipopolysaccharide; L-NAME, N-nitro-L-ar-
ginine methyl ester; NO, nitric oxide; SD, standard deviation.
Additional file 4: Figure S4. BV2 microglia and MSC show distinct
CD45 expression. Scatter plots show CD45 expression of (a) BV2
microglia, (b) MSC and (c) co-culture after 48 hours in culture. (d)
Distribution of viable (lower left), early apoptotic (lower right), late
apoptotic (upper right) and necrotic (upper left) population in DMSO
treated BV2 cells (positive control for apoptosis assay) as determined by
Annexin-V/PI staining. Numbers within each quadrant of plot indicate
percentage of cells. Results are from a representative of three independent
experiments. MSC, mesenchymal stem cells; PI, propidium iodide.
Additional file 5: Table S1. Co-culture does not induce apoptosis in
BV2 cells and MSC. Table shows apoptosis assay results of BV2 microglia
and MSC at 48 hours after co-culture. Results are expressed as mean ± SD
from three independent experiments. BV2, BV2 microglia; LPS,
lipopolysaccharide; MSC, mesenchymal stem cells; SD, standard deviation.
Additional file 6: Figure S5. Microglia-induced cell cycle arrest of MSC
is not because of contact inhibition or nutrient deprivation. BV2 and MSC
were co-cultured at a 1:0.2 ratio at a seeding density 10-fold lower than
usual and were stimulated with 1 μg/ml LPS after overnight incubation.
Cells were harvested 48 hours post-LPS stimulation and cell cycle was
analysed by propidium iodide staining. Separation of BV2 and MSC
populations on flow cytometry was enabled by CD45 staining. LPS,
lipopolysaccharide; MSC, mesenchymal stem cells.
Abbreviations
CNS: central nervous system; DMEM: Dulbecco's modified Eagle's medium;
3H-TdR: tritiated thymidine; Ig: immunoglobulin; IL: interleukin;
iNOS: inducible nitric oxide synthase; L-NAME: N-nitro-L-arginine methyl
ester; LPS: lipopolysaccharide; MSC: mesenchymal stem cells; NO: nitric oxide;PBS: phosphate-buffered saline; PI: propidium iodide; TNF: tumour
necrosis factor.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SJ designed and conducted the experiments, analysed the data and wrote
the manuscript. SWT performed the Griess assays. YYO performed the
cytometric bead array. RR assessed the cell cycle data. SV conceived and
designed the study, obtained funding for the work, and analysed the data.
All authors read and approved the final.
Acknowledgements
We thank Tong Chih Kong for his assistance with the apoptosis assay,
Catherine Chieng Cheng Yun for discussions and critical comments on the
manuscript, and Marsitah Abdul Jalil for maintaining the flow cytometer facility.
This study was funded by the ScienceFund (Ministry of Science, Technology
and Innovation, Malaysia) [02-01-04-SF1538] and Exploratory Research Grant
Scheme (Ministry of Higher Education, Malaysia) [ERGS/1/2012/5527106].
Author details
1Neuroinflammation Group, Immunology Laboratory, Department of
Pathology, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia,
43400 Serdang, Selangor, Malaysia. 2Genetic Medicine Research Centre,
Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400
Serdang, Selangor, Malaysia. 3Current address: Tissue Engineering Centre,
Universiti Kebangsaan Malaysia Medical Centre, 56000 Kuala Lumpur,
Malaysia. 4Department of Anatomy, Yong Loo Lin School of Medicine, NUS,
MD10, 4 Medical Drive, Singapore 117597, Singapore. 5Stem Cells &
Immunity Group, Immunology Laboratory, Department of Pathology, Faculty
of Medicine and Health Sciences, Universiti Putra Malaysia, 43400 Serdang,
Selangor, Malaysia.
Received: 19 May 2014 Accepted: 9 August 2014
Published: 3 September 2014
References
1. Ooi YY, Rahmat Z, Jose S, Ramasamy R, Vidyadaran S: Immunophenotype
and differentiation capacity of bone marrow-derived mesenchymal stem
cells from CBA/Ca, ICR and Balb/c mice. World J Stem Cells 2013, 5:34–42.
2. Uccelli A, Moretta L, Pistoia V: Mesenchymal stem cells in health and
disease. Nat Rev Immunol 2008, 8:726–736.
3. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E,
Sundberg B, Bernardo ME, Remberger M, Dini G, Egeler RM, Bacigalupo A,
Fibbe W, Ringden O: Mesenchymal stem cells for treatment of
steroid-resistant, severe, acute graft-versus-host disease: a phase II
study. Lancet 2008, 371:1579–1586.
4. Fisher-Shoval Y, Barhum Y, Sadan O, Yust-Katz S, Ben-Zur T, Lev N, Benkler C,
Hod M, Melamed E, Offen D: Transplantation of placenta-derived
mesenchymal stem cells in the EAE mouse model of MS. J Mol Neurosci
2012, 48:176–184.
5. Gutierrez-Fernandez M, Rodriguez-Frutos B, Ramos-Cejudo J, Teresa Vallejo-
Cremades M, Fuentes B, Cerdan S, Diez-Tejedor E: Effects of intravenous
administration of allogenic bone marrow- and adipose tissue-derived
mesenchymal stem cells on functional recovery and brain repair markers
in experimental ischemic stroke. Stem Cell Res Ther 2013, 4:11.
6. Boucherie C, Schafer S, Lavand’homme P, Maloteaux JM, Hermans E:
Chimerization of astroglial population in the lumbar spinal cord after
mesenchymal stem cell transplantation prolongs survival in a rat model
of amyotrophic lateral sclerosis. J Neurosci Res 2009, 87:2034–2046.
7. Abrams MB, Dominguez C, Pernold K, Reger R, Wiesenfeld-Hallin Z, Olson L,
Prockop D: Multipotent mesenchymal stromal cells attenuate chronic
inflammation and injury-induced sensitivity to mechanical stimuli in
experimental spinal cord injury. Restor Neurol Neurosci 2009, 27:307–321.
8. Pileggi A: Mesenchymal stem cells for the treatment of diabetes. Diabetes
2012, 61:1355–1356.
9. Alfaro MP, Pagni M, Vincent A, Atkinson J, Hill MF, Cates J, Davidson JM,
Rottman J, Lee E, Young PP: The Wnt modulator sFRP2 enhances
mesenchymal stem cell engraftment, granulation tissue formation and
myocardial repair. Proc Natl Acad Sci U S A 2008, 105:18366–18371.
Jose et al. Journal of Neuroinflammation 2014, 11:149 Page 12 of 13
http://www.jneuroinflammation.com/content/11/1/14910. Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E, Dazzi F: Bone
marrow mesenchymal stem cells inhibit the response of naive and
memory antigen-specific T cells to their cognate peptide. Blood 2003,
101:3722–3729.
11. Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F,
Risso M, Gualandi F, Mancardi GL, Pistoia V, Uccelli A: Human mesenchymal
stem cells modulate B-cell functions. Blood 2006, 107:367–372.
12. Glennie S, Soeiro I, Dyson PJ, Lam EW, Dazzi F: Bone marrow mesenchymal
stem cells induce division arrest anergy of activated T cells. Blood 2005,
105:2821–2827.
13. Jiang XX, Zhang Y, Liu B, Zhang SX, Wu Y, Yu XD, Mao N: Human
mesenchymal stem cells inhibit differentiation and function of
monocyte-derived dendritic cells. Blood 2005, 105:4120–4126.
14. Ramasamy R, Fazekasova H, Lam EW, Soeiro I, Lombardi G, Dazzi F:
Mesenchymal stem cells inhibit dendritic cell differentiation and
function by preventing entry into the cell cycle. Transplantation 2007,
83:71–76.
15. English K, Barry FP, Mahon BP: Murine mesenchymal stem cells suppress
dendritic cell migration, maturation and antigen presentation. Immunol
Lett 2008, 115:50–58.
16. Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, Gokhan S, Mehler MF,
Conway SJ, Ng LG, Stanley ER, Samokhvalov IM, Merad M: Fate mapping
analysis reveals that adult microglia derive from primitive macrophages.
Science 2010, 330:841–845.
17. Hughes V: Microglia: the constant gardeners. Nature 2012, 485:570–572.
18. Hanisch UK, Kettenmann H: Microglia: active sensor and versatile
effector cells in the normal and pathologic brain. Nat Neurosci 2007,
10:1387–1394.
19. Schafer DP, Lehrman EK, Kautzman AG, Koyama R, Mardinly AR, Yamasaki R,
Ransohoff RM, Greenberg ME, Barres BA, Stevens B: Microglia sculpt
postnatal neural circuits in an activity and complement-dependent
manner. Neuron 2012, 74:691–705.
20. Tremblay ME, Lowery RL, Majewska AK: Microglial interactions with
synapses are modulated by visual experience. PLoS Biol 2010, 8:e1000527.
21. Nimmerjahn A, Kirchhoff F, Helmchen F: Resting microglial cells are highly
dynamic surveillants of brain parenchyma in vivo. Science 2005,
308:1314–1318.
22. Aguzzi A, Barres BA, Bennett ML: Microglia: scapegoat, saboteur, or
something else? Science 2013, 339:156–161.
23. Gomes C, Ferreira R, George J, Sanches R, Rodrigues DI, Goncalves N,
Cunha RA: Activation of microglial cells triggers a release of brain-derived
neurotrophic factor (BDNF) inducing their proliferation in an adenosine
A2A receptor-dependent manner: A2A receptor blockade prevents BDNF
release and proliferation of microglia. J Neuroinflammation 2013, 10:16.
24. Burguillos MA, Deierborg T, Kavanagh E, Persson A, Hajji N, Garcia-Quintanilla A,
Cano J, Brundin P, Englund E, Venero JL, Joseph B: Caspase signalling
controls microglia activation and neurotoxicity. Nature 2011,
472:319–324.
25. Ghoshal A, Das S, Ghosh S, Mishra MK, Sharma V, Koli P, Sen E, Basu A:
Proinflammatory mediators released by activated microglia induces
neuronal death in Japanese encephalitis. Glia 2007, 55:483–496.
26. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, Choi DK,
Ischiropoulos H, Przedborski S: Blockade of microglial activation is
neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
mouse model of Parkinson disease. J Neurosci 2002, 22:1763–1771.
27. Saijo K, Crotti A, Glass CK: Regulation of microglia activation and
deactivation by nuclear receptors. Glia 2013, 61:104–111.
28. Ooi YY, Ramasamy R, Rahmat Z, Subramaiam H, Tan SW, Abdullah M,
Israf DA, Vidyadaran S: Bone marrow-derived mesenchymal stem
cells modulate BV2 microglia responses to lipopolysaccharide.
Int Immunopharmacol 2010, 10:1532–1540.
29. Zhou C, Zhang C, Chi S, Xu Y, Teng J, Wang H, Song Y, Zhao R: Effects of
human marrow stromal cells on activation of microglial cells and
production of inflammatory factors induced by lipopolysaccharide.
Brain Res 2009, 1269:23–30.
30. Lanza C, Morando S, Voci A, Canesi L, Principato MC, Serpero LD, Mancardi G,
Uccelli A, Vergani L: Neuroprotective mesenchymal stem cells are
endowed with a potent antioxidant effect in vivo. J Neurochem 2009,
110:1674–1684.
31. Lee JK, Jin HK, Bae JS: Bone marrow-derived mesenchymal stem cells
reduce brain amyloid-beta deposition and accelerate the activation ofmicroglia in an acutely induced Alzheimer’s disease mouse model.
Neurosci Lett 2009, 450:136–141.
32. Kim JY, Kim DH, Kim JH, Lee D, Jeon HB, Kwon SJ, Kim SM, Yoo YJ, Lee EH,
Choi SJ, Seo SW, Lee JI, Na DL, Yang YS, Oh W, Chang JW: Soluble
intracellular adhesion molecule-1 secreted by human umbilical cord
blood-derived mesenchymal stem cell reduces amyloid-beta plaques.
Cell Death Differ 2012, 19:680–691.
33. Blasi E, Barluzzi R, Bocchini V, Mazzolla R, Bistoni F: Immortalization of
murine microglial cells by a v-raf/v-myc carrying retrovirus.
J Neuroimmunol 1990, 27:229–237.
34. Rahmat Z, Jose S, Ramasamy R, Vidyadaran S: Reciprocal interactions of
mouse bone marrow-derived mesenchymal stem cells and BV2 microglia
following lipopolysaccharide stimulation. Stem Cell Res Ther 2013, 4:12.
35. Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI, Zhao RC, Shi Y:
Mesenchymal stem cell-mediated immunosuppression occurs via concerted
action of chemokines and nitric oxide. Cell Stem Cell 2008, 2:141–150.
36. Sato K, Ozaki K, Oh I, Meguro A, Hatanaka K, Nagai T, Muroi K, Ozawa K:
Nitric oxide plays a critical role in suppression of T-cell proliferation by
mesenchymal stem cells. Blood 2007, 109:228–234.
37. Plumas J, Chaperot L, Richard MJ, Molens JP, Bensa JC, Favrot MC:
Mesenchymal stem cells induce apoptosis of activated T cells. Leukemia
2005, 19:1597–1604.
38. Ramasamy R, Lam EW, Soeiro I, Tisato V, Bonnet D, Dazzi F: Mesenchymal
stem cells inhibit proliferation and apoptosis of tumor cells: impact on
in vivo tumor growth. Leukemia 2007, 21:304–310.
39. Block ML, Zecca L, Hong JS: Microglia-mediated neurotoxicity: uncovering
the molecular mechanisms. Nat Rev Neurosci 2007, 8:57–69.
40. Vroon A, Drukarch B, Bol JG, Cras P, Breve JJ, Allan SM, Relton JK, Hoogland PV,
Van Dam AM: Neuroinflammation in Parkinson’s patients and MPTP-treated
mice is not restricted to the nigrostriatal system: microgliosis and
differential expression of interleukin-1 receptors in the olfactory bulb.
Exp Gerontol 2007, 42:762–771.
41. Groebe A, Clarner T, Baumgartner W, Dang J, Beyer C, Kipp M: Cuprizone
treatment induces distinct demyelination, astrocytosis, and microglia cell
invasion or proliferation in the mouse cerebellum. Cerebellum 2009,
8:163–174.
42. Li T, Pang S, Yu Y, Wu X, Guo J, Zhang S: Proliferation of parenchymal
microglia is the main source of microgliosis after ischaemic stroke.
Brain 2013, 136:3578–3588.
43. Yan K, Zhang R, Sun C, Chen L, Li P, Liu Y, Peng L, Sun H, Qin K, Chen F,
Huang W, Chen Y, Lv B, Du M, Zou Y, Cai Y, Qin L, Tang Y, Jiang X: Bone
marrow-derived mesenchymal stem cells maintain the resting
phenotype of microglia and inhibit microglial activation. PLoS One 2013,
8:e84116.
44. Tolar J, Nauta AJ, Osborn MJ, Panoskaltsis Mortari A, McElmurry RT, Bell S,
Xia L, Zhou N, Riddle M, Schroeder TM, Westendorf JJ, McIvor RS,
Hogendoorn PC, Szuhai K, Oseth L, Hirsch B, Yant SR, Kay MA, Peister A,
Prockop DJ, Fibbe WE, Blazar BR: Sarcoma derived from cultured
mesenchymal stem cells. Stem Cells 2007, 25:371–379.
45. Jeong JO, Han JW, Kim JM, Cho HJ, Park C, Lee N, Kim DW, Yoon YS:
Malignant tumor formation after transplantation of short-term cultured
bone marrow mesenchymal stem cells in experimental myocardial
infarction and diabetic neuropathy. Circ Res 2011, 108:1340–1347.
46. van den Berk LC, Jansen BJ, Siebers-Vermeulen KG, Roelofs H, Figdor CG,
Adema GJ, Torensma R: Mesenchymal stem cells respond to TNF but do
not produce TNF. J Leukoc Biol 2010, 87:283–289.
47. Jekabsone A, Mander PK, Tickler A, Sharpe M, Brown GC: Fibrillar beta-amyloid
peptide Abeta1-40 activates microglial proliferation via stimulating
TNF-alpha release and H2O2 derived from NADPH oxidase: a cell
culture study. J Neuroinflammation 2006, 3:24.
48. Barcia C, Ros CM, Annese V, Gomez A, Ros-Bernal F, Aguado-Yera D,
Martinez-Pagan ME, de Pablos V, Fernandez-Villalba E, Herrero MT: IFN-gamma
signaling, with the synergistic contribution of TNF-alpha, mediates cell
specific microglial and astroglial activation in experimental models of
Parkinson’s disease. Cell Death Dis 2011, 2:e142.
49. Ferger B, Leng A, Mura A, Hengerer B, Feldon J: Genetic ablation of tumor
necrosis factor-alpha (TNF-alpha) and pharmacological inhibition of
TNF-synthesis attenuates MPTP toxicity in mouse striatum. J Neurochem
2004, 89:822–833.
50. Zhang R, Liu Y, Yan K, Chen L, Chen XR, Li P, Chen FF, Jiang XD:
Anti-inflammatory and immunomodulatory mechanisms of
Jose et al. Journal of Neuroinflammation 2014, 11:149 Page 13 of 13
http://www.jneuroinflammation.com/content/11/1/149mesenchymal stem cell transplantation in experimental traumatic brain
injury. J Neuroinflammation 2013, 10:106.
51. Najar M, Raicevic G, Jebbawi F, De Bruyn C, Meuleman N, Bron D, Toungouz M,
Lagneaux L: Characterization and functionality of the CD200-CD200R
system during mesenchymal stromal cell interactions with T-lymphocytes.
Immunol Lett 2012, 146:50–56.
52. Nasef A, Mathieu N, Chapel A, Frick J, Francois S, Mazurier C, Boutarfa A,
Bouchet S, Gorin NC, Thierry D, Fouillard L: Immunosuppressive effects of
mesenchymal stem cells: involvement of HLA-G. Transplantation 2007,
84:231–237.
53. Luz-Crawford P, Noel D, Fernandez X, Khoury M, Figueroa F, Carrion F,
Jorgensen C, Djouad F: Mesenchymal stem cells repress Th17 molecular
program through the PD-1 pathway. PLoS One 2012, 7:e45272.
doi:10.1186/s12974-014-0149-8
Cite this article as: Jose et al.: Mesenchymal stem cells exert
anti-proliferative effect on lipopolysaccharide-stimulated BV2 microglia
by reducing tumour necrosis factor-α levels. Journal of Neuroinflammation
2014 11:149.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
